Table 4.
Drug/Dose-Specific Placebo-Adjusted Results
| Study and Drug/Dose | Difference in Δ6MWD, m (95% CI) |
OR for Clinical Events (95% CI) |
Meta-Regression Weight |
|---|---|---|---|
| ARIES-1 | |||
| Ambrisentan 5 mg | 24.9 (0.32–49.4) | 0.58 (0.13–2.53) | 1.8 |
| Ambrisentan 10 mg | 41.4 (15.6–67.2) | 0.38 (0.07–2.04) | 1.4 |
| ARIES-2 | |||
| Ambrisentan 2.5 mg | 37.3 (8.2–66.3) | 0.35 (0.11–1.12) | 2.8 |
| Ambrisentan 5 mg | 53.6 (24.4–82.8) | 0.22 (0.06–0.88) | 2.1 |
| BREATHE-1 | |||
| Bosentan 125 mg | 33.4 (8.6–58.3) | 0.58 (0.12–2.80) | 1.5 |
| Bosentan 250 mg | 46.3 (21.1–71.6) | 0.42 (0.07–2.47) | 1.2 |
| AIR | |||
| Iloprost | 24.5 (−2.4–51.3) | 0.47 (0.23–0.96) | 7.3 |
| STRIDE-1 | |||
| Sitaxsentan 100 mg | 33.3 (9.1–57.4) | 0.20 (0.02–1.99) | 0.7 |
| Sitaxsentan 300 mg | 24.6 (−0.45–49.7) | 0.36 (0.06–2.15) | 1.2 |
| STRIDE-2 | |||
| Sitaxsentan 50 mg | −7.1 (−27.6–13.5) | 0.54 (0.09–3.20) | 1.2 |
| Sitaxsentan 100 mg | 15.2 (−4.7–35.1) | 0.77 (0.13–4.72) | 1.2 |
| STRIDE-4 | |||
| Sitaxsentan 50 mg | −19.1 (−49.9–11.8) | 0.71 (0–4.42)* | <0.1 |
| Sitaxsentan 100 mg | 6.9 (−23.5–37.5) | 0.73 (0–2.07)* | <0.1 |
| SUPER | |||
| Sildenafil 20 mg | 39.3 (15.0–63.6) | 0.36 (0.09–1.47) | 1.9 |
| Sildenafil 40 mg | 45.2 (20.6–69.8) | 0.25 (0.05–1.28) | 1.5 |
| Sildenafil 80 mg | 42.1 (18.0–66.3) | 0.59 (0.17–1.98) | 2.6 |
| PHIRST | |||
| Tadalafil 2.5 mg | −0.3 (−20.7–20.0) | 0.49 (0.18–1.34) | 3.8 |
| Tadalafil 10 mg | 17.1 (−4.3–38.5) | 0.30 (0.10–0.90) | 3.1 |
| Tadalafil 20 mg | 24.6 (5.1–44.1) | 0.59 (0.23–1.51) | 4.4 |
| Tadalafil 40 mg | 18.2 (−2.2–38.6) | 0.27 (0.08–0.90) | 2.7 |
| Treprostinil | |||
| Treprostinil | 9.9 (−6.7–26.4) | 0.52 (0.27–0.99) | 9.2 |
| Summary† | 22.4 (17.4–27.5) | 0.44 (0.33–0.57) |
6MWD indicates 6-minute walk distance; CI, confidence interval; OR, odds ratio; ARIES, Ambrisentan in Pulmonary Arterial Hypertension, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy Studies; BREATHE, Bosentan: Randomized Trial of Endothelin receptor Antagonist Therapy; AIR, Aerosolized Iloprost Randomized; STRIDE, Sitaxsentan To Relieve Impaired Exercise; SUPER, Sildenafil Use in Pulmonary Hypertension; and PHIRST, Pulmonary Arterial Hypertension and Response to Tadalafil.
Reference group is the placebo group in each study. All analyses are adjusted for baseline walk distance.
Obtained from exact logistic regression.
Obtained from fixed-effects meta-analysis (P for heterogeneity=0.99).